Group 1: Financial Performance - The overall gross margin for the company's proprietary brands is approximately 50% [1] - Revenue from proprietary brands is expected to grow nearly 30% year-on-year by 2024, indicating a strong growth trend [1] - The current revenue share from proprietary brands is relatively low, but is anticipated to increase with enhanced sales resource investment and product pipeline expansion [1] Group 2: Research and Development - The company is focusing its R&D investments primarily in the fields of antibodies and proteins [1] - As of the end of 2024, the Hangzhou antibody R&D center has developed over 2,900 SPUs (Standard Product Units) including paired antibodies and diagnostic antibodies [1] - The Nanjing protein R&D center has developed over 1,700 SPUs, including drug targets and cytokines, and has introduced new products like one-step Elisa kits [1] Group 3: Share Repurchase and Incentive Plans - In 2024, the company initiated a share repurchase plan, utilizing 25,987,076 CNY to buy back 927,600 shares, intended for equity incentives or employee stock ownership plans [1] - A new share repurchase plan is set to use between 15 million and 30 million CNY of its own funds for share buybacks aimed at capital reduction [1][2] - Future equity incentive plans will be introduced based on business development needs to enhance motivational effects [2] Group 4: Mergers and Acquisitions Strategy - The company aims to strengthen channel and R&D capabilities to better serve customers and provide diverse product offerings [2] - In terms of external growth, the company will seek potential upstream and downstream acquisition targets that align with its existing business, particularly in antibody-related applications [2]

证券代码：301166 证券简称：优宁维 公告编号：2025-063 上海优宁维生物科技股份有限公司 关于注销募集资金专项账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意上海优宁维生物科技股份有限 公司首次公开发行股票注册的批复》（证监许可〔2021〕3556 号）同意注册， 并经深圳证券交易所同意，上海优宁维生物科技股份有限公司（以下简称"公司"） 首次公开发行人民币普通股（A 股）股票 2,166.6668 万股，每股面值为人民币 1.00 元，发行价格为人民币 86.06 元/股，募集资金总额为人民币 186,463.34 万元， 扣除发行费用人民币 26,911.62 万元（不含税）后，实际募集资金净额为人民币 159,551.73 万元。 | 账户名称 | 开户银行 | 专户账号 | 注销前账户余额（元） | | --- | --- | --- | --- | | 公司 | 招商银行股份有限公司上海四平支行 | 121923691110118 | 0 | | 公司 | 中国民生 ...

Core Viewpoint - The company is positioned as a one-stop service provider in life sciences, focusing on integrating both domestic and international brands to meet customer needs, with a significant growth in its own brand products expected in the future [1][2]. Product Structure - The company offers a range of products and services including reagents, consumables, instruments, and laboratory services, primarily focusing on agency products supplemented by its own brand products [1]. - In 2024, the revenue from the company's own brand products is expected to grow nearly 30% year-on-year, indicating a strong growth trend [2]. Profitability and Revenue Growth - The overall gross margin for the company's own brand products is approximately 50%, with a low current revenue share from these products [2]. - The company plans to increase the revenue share of its own brand products by investing more resources into sales and expanding its product pipeline [2]. Shareholder Incentives - In 2024, the company initiated a share repurchase plan, utilizing 25,987,076 yuan to buy back 927,600 shares, which will be used for equity incentives or employee stock ownership plans [3]. - Future equity incentive plans will be introduced based on business development needs to enhance motivation [3]. International Market Expansion - The company's operations are primarily domestic, but it plans to accelerate the internationalization of its own brand products based on R&D and domestic sales performance, including establishing overseas subsidiaries [4]. - The company has already set up a subsidiary in Singapore in 2024 and is actively enhancing product visibility through online marketing and participation in offline exhibitions [4]. M&A Strategy - The company aims to strengthen its channel and R&D capabilities to better serve customers and provide a diverse range of products and services [5]. - In terms of external growth, the company will seek potential upstream and downstream acquisition targets that align with its existing business, particularly in antibody-related applications [5].

Group 1 - The stock price of You Ning Wei is 34.05 yuan, down 0.21 yuan from the previous trading day, with a trading range of 33.73 yuan to 34.55 yuan and a trading volume of 15,874 hands, amounting to 54 million yuan [1] - You Ning Wei operates in the biopharmaceutical industry, focusing on the research, production, and sales of life science reagents and related products, with headquarters in Shanghai [1] - As of August 4, You Ning Wei was surveyed by one fund company, and among the six companies surveyed that day, its total market capitalization was less than 10 billion yuan [1] Group 2 - On August 5, the net outflow of main funds from You Ning Wei was 2.0785 million yuan, accounting for 0.11% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow reached 3.3885 million yuan, representing 0.18% of the circulating market value [1]

市场表现上，基金调研股中，近5日上涨的有5只，涨幅居前的有威尔高、优宁维、科士达等，涨幅为 5.59%、2.10%、1.54%；下跌的有1只，跌幅居前的有中旗新材等，跌幅为4.35%。 业绩方面，基金调研公司中，公布上半年业绩预告的共有2家，业绩预告类型来看，预增有1只。以净利 润增幅中值来看，净利润增幅最高的是威尔高，预计净利润中值为4650.00万元，同比增幅为21.71%。 （数据宝） 8月4日基金调研公司一览 昨日基金共对6家公司进行调研，扎堆调研东威科技、泰恩康等。 证券时报·数据宝统计，8月4日共8家公司被机构调研，按调研机构类型看，基金参与6家公司的调研活 动。东威科技最受关注，参与调研的基金达59家；泰恩康、威尔高等分别获38家、3家基金集体调研。 基金参与调研的公司中，按所属板块统计，深市主板公司有2家，创业板公司有3家，科创板公司有1 家。 从基金调研公司的A股总市值统计，总市值不足100亿元的有3家，分别是优宁维、威尔高、中旗新材 等。 | 代码 | 简称 | 基金家数 | 最新收盘价（元） | 近5日涨跌幅（%） | 行业 | | --- | --- | --- | --- | --- ...

Group 1: Research Basic Information - The research object is Youningwei, belonging to the professional services industry, with a reception time of August 4, 2025. The listed company's reception staff includes Deputy General Manager and Board Secretary Qi Yanfang, and Securities Affairs Representative Xia Qingli [17] Group 2: Detailed Research Institutions - The reception objects include Huitong Fund (a fund management company) and Tianling Investment (an investment company) [18] Group 3: Main Content Information - The company is a one - stop service provider in life sciences, offering products and services such as reagents, consumables, instruments, and laboratory services. It currently has a product structure with agency products as the main part and self - owned brand products as a supplement. In 2024, the total revenue of self - owned brand products increased by nearly 30% year - on - year [22] - The overall gross margin of the company's self - owned brand is about 50%, and the revenue is expected to increase in proportion as the company invests more in sales resources and enriches product pipelines [22] - In 2024, the company launched a share repurchase plan, using 25,987,076 yuan of its own funds to repurchase 927,600 shares for equity incentives or employee stock ownership plans, and will launch relevant plans according to business development [22] - The company's business is mainly in the domestic market. It will accelerate the overseas expansion of self - owned brand products based on R & D and domestic sales, and established a company in Singapore in 2024. It also promotes products through online and offline means [22][23] - The company will strengthen channel and R & D capabilities around the "Two Extremes Strategy". In terms of external expansion, it will seek investment and cooperation with potential upstream and downstream target enterprises with synergistic effects, mainly product - type companies related to antibody applications [23]

Group 1: Company Product Structure - The company operates as a one-stop service provider in life sciences, offering reagents, consumables, instruments, and laboratory services, integrating both well-known domestic and international brands as well as its own brands [1] - In 2024, the revenue from the company's own brands increased by nearly 30% year-on-year, indicating a strong growth trend [1] Group 2: Own Brand Performance - The overall gross margin for the company's own brands is approximately 50% [1] - The revenue share from own brands is currently low, but it is expected to increase as the company invests more resources into sales and continues to enrich its product pipeline [1] Group 3: Shareholder Incentives - In 2024, the company initiated a share repurchase plan, utilizing a total of 25,987,076 CNY to repurchase 927,600 shares, which will be used for equity incentives or employee stock ownership plans [1] - Future equity incentive or employee stock ownership plans will be introduced based on business development needs [1] Group 4: Overseas Market Expansion - The company's business is primarily focused on the domestic market, but it plans to accelerate the internationalization of its own brand products based on R&D and domestic sales performance [2] - In 2024, the company established a subsidiary in Singapore to facilitate overseas expansion [2] - The company is actively enhancing product visibility through online promotions and participation in offline exhibitions to further accelerate overseas market development [2] Group 5: M&A Strategy - The company aims to strengthen channel capabilities and R&D capabilities to better serve customers and provide a diverse range of products and services [2] - In terms of external growth, the company will seek potential upstream and downstream acquisition targets that align with its existing business, particularly in antibody-related applications [2]

优宁维（301166.SZ）8月4日在投资者互动平台表示，投资者您好，公司参与投资的股权投资基金主要 投向医疗健康、数字经济、先进制造等领域。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：介绍下贵公司的创投投资了哪几个主要企业，他们前 景如何？ ...

Core Viewpoint - The company has approved the use of idle raised funds and self-owned funds for cash management, with a total limit of RMB 180 million, ensuring that it does not affect project construction or normal operations [1] Group 1: Cash Management Approval - The company and its subsidiaries are authorized to use up to RMB 30 million of idle raised funds and RMB 150 million of self-owned funds for cash management, effective for 12 months starting from March 9, 2025 [1] - Independent directors and the sponsor institution have expressed their agreement with the cash management proposal [1] Group 2: Investment Risk Analysis - The company plans to invest in structured deposit products, which are considered low-risk, but acknowledges potential market volatility affecting returns [2] - Risk control measures include timely analysis of cash management products and maintaining close contact with financial institutions to monitor fund operations [2][3] Group 3: Impact on Daily Operations - The use of idle self-owned funds for cash management is based on principles of risk prevention and prudent investment, ensuring the safety of the principal [5] - This approach is expected to enhance fund utilization efficiency and generate investment returns, ultimately benefiting the company and its shareholders [5] Group 4: Previous Cash Management Activities - As of August 1, 2025, the company has an outstanding balance of RMB 70 million in raised funds and RMB 920 million in self-owned funds invested in structured deposit products [6]

Core Viewpoint - The company has approved a share repurchase plan, intending to buy back shares using its own funds within a specified price range and timeframe [1][2]. Summary by Sections Share Repurchase Plan - The company plans to repurchase shares with a budget between RMB 15 million and RMB 30 million, with a maximum repurchase price set at RMB 44 per share [1]. - Following the annual equity distribution on May 22, 2025, the maximum repurchase price was adjusted to RMB 43.77 per share [2]. Progress of Share Repurchase - As of July 31, 2025, the company has not yet repurchased any shares, with the total repurchased shares standing at 0, which is 0% of the total share capital [2]. Compliance and Regulations - The share repurchase plan complies with relevant laws, regulations, and the company's own guidelines [3][4]. - The company has not engaged in share repurchase during periods that could significantly impact the trading price of its securities [4]. - The repurchase will be conducted through centralized bidding, adhering to specific trading restrictions [5]. Future Actions - The company will continue to implement the repurchase plan based on market conditions and will fulfill its information disclosure obligations as required by law [5].